Q1 2023 Non-GAAP Operating Income

Promising Late-Stage Assets Poised to Support Growth 40 | 15 | Olanzapine LAI ('749) Potential to be first long-acting olanzapine with a favorable safety profile ICS/SABA ('248) De-risked¹ ICS/SABA fixed-dose addressing market needs Anti-TL1-A (574) Potential to be best-in-class for proven TL1A mechanism in UC/CD LAI: Long-Acting Injectable, UC: Ulcerative Colitis, CD: Crohn's Disease, ICS: Inhaled Corticosteroids, SABA: Short-Acting Beta Agonist 1. De-risked referring to an increased probability of success in clinical trials teva

View entire presentation